

## REVIEW ARTICLE

# Zika Virus - A Review for Family Physicians

Marie Florent-Carre, MPH, DO,<sup>1</sup> Gina Foster-Moumoutjis, MD,<sup>1</sup>

Cyril Blavo, MS, DO, MPH & TM, FACOP,<sup>1</sup> Luzan Phillpotts, DO, MPH,<sup>1</sup> Traci-lyn Eisenberg, DO,<sup>1</sup> & Bindu S. Mayi, MSc, PhD<sup>2</sup>

<sup>1</sup>Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University

<sup>2</sup>College of Medical Sciences, Nova Southeastern University

## KEYWORDS:

Zika Virus

Nucleic  
Amplification  
Testing

Guillain-Barre  
Syndrome

Microcephaly

Prevention and  
Wellness

Mosquito-borne viruses have been on the rise in recent years. This becomes especially critical when you consider a virus with a particularly harrowing consequence, like the Zika virus (ZIKV) and infant microcephaly. From its obscure history in Africa, ZIKV diverged into an African and Asian strain, the latter strain traveling from Asia to the islands in the Pacific Ocean and ultimately to the Americas, including the United States. ZIKV spread through this immunologically naïve population through mosquito bites, sexual transmission, intrauterine transmission and blood transfusion. Zika symptoms may include fever, joint pain, and maculopapular rash, all of which are common to other mosquito-borne illnesses such as dengue and chikungunya, also seen in similar locations. Awareness of the symptoms, differential diagnosis and the testing algorithm for Zika may improve detection and facilitate early management. Tests for ZIKV include nucleic amplification assays, IgM serology, and the plaque reduction neutralization test, with decision to test determined by symptom status, pregnancy status, and degree of exposure. While the majority of patients with ZIKV are asymptomatic, the most severe complications are Guillain-Barré Syndrome for adults and Congenital Zika Syndrome for infants born to infected mothers. Since the mainstay of management is supportive care and surveillance, preventive strategies are critical in prevention of these complications. Prevention is multimodal including mosquito population control, mosquito bite prevention, and actions to prevent sexual transmission. Through counseling and early detection, the family medicine practitioner has the unique opportunity to prevent the spread of ZIKV and its potential complications.

## INTRODUCTION

In 2016, the World Health Organization (WHO) declared Zika virus (ZIKV) infection a public health emergency of international concern.<sup>1</sup> The virus had spread to 26 countries and territories in the Americas, infecting thousands of individuals and causing complications such as Guillain-Barré Syndrome (GBS) in adults and severe microcephaly in infants born to infected mothers. The increased cases of microcephaly caught the attention of public health authorities and health professionals, compounded by the fact that microcephaly had not been associated with any arbovirus infection to date. Since ZIKV is a reemerging virus with the potential to cause complications, it is important for health professionals to be informed about ZIKV so they can recognize this threat. This paper provides a comprehensive description of the history, transmission, clinical manifestations, diagnosis and prevention of ZIKV infection.

ZIKV belongs to the Flaviviridae family of viruses, which also consists of other important human pathogens such as West Nile encephalitis virus (WNEV), Dengue virus (DENV), Yellow fever virus and Japanese encephalitis virus (JEV).<sup>2</sup> Before the current outbreak, ZIKV had an unremarkable history. In 1947, Yellow Fever researchers first isolated the virus from a caged Rhesus monkey in the Zika forest of Uganda.<sup>3</sup> From Africa, ZIKV made its way to Asia, where in 1954, it was isolated from mosquitoes in Malaysia and by 1977, it had been isolated from patients in Indonesia.<sup>4,5</sup> Phylogeny reveals two distinct lineages of ZIKV, African and Asian. In 2007, the Asian lineage of ZIKV affected about 70 percent of the population on Yap island in the Federated States of Micronesia, presumably after having arrived from Southeast Asia by air travel.<sup>6</sup> Data implicate this Asian lineage in the ZIKV outbreak in the Americas.<sup>7</sup> After Yap Island, ZIKV infected French Polynesia, other islands across the Pacific Ocean, and subsequently Brazil and the Americas, where it gained notoriety for its complications of microcephaly and GBS.<sup>8</sup> Based on phylogeny, researchers postulate that ZIKV was introduced to Brazil sometime between August 2013 and July 2014.<sup>9</sup> ZIKV infection of this immunologically naïve population may have facilitated its rapid spread in Brazil and neighboring countries. It is thought that the virus circulated undetected for about a year, either because of subclinical

## CORRESPONDENCE:

Marie Florent-Carre, MPH, DO | [mflorent@nova.edu](mailto:mflorent@nova.edu)

infections or because of misdiagnosis of Zika (ZIKV disease) as one of the other endemic arboviral illnesses, such as Dengue and Chikungunya.

On July 29, 2016, the continental United States (U.S.) recorded its first case of a local, mosquito-borne ZIKV infection in Miami-Dade County, Florida.<sup>10,11</sup> Following this initial report, ZIKV infection was reported in Hidalgo County, Texas.<sup>11,12</sup> ZIKV is not the first arbovirus to cause an outbreak in the United States. The CDC website accounts for provisional Zika cases in the U.S. and its territories, according to which the total number of symptomatic Zika cases in the U.S. from 2015 to 2018 have been 5,700. The number of presumed locally transmitted cases was 231, with Florida showing the highest number at 220 and Texas showing 11 cases. There have been short-lived outbreaks with other arboviruses, such as DENV and Chikungunya virus (CHIKV), in regions of Texas and Florida, when the *Aedes aegypti* mosquito populations were abundant.<sup>13</sup> In 2016, mosquito surveillance data revealed that approximately one out of 1,600 *Aedes aegypti* mosquitoes were infected with ZIKV, an infection rate that is consistent with outbreaks of DENV and CHIKV.<sup>14,15</sup> Furthermore, research has shown that human ZIKV infection correlates with abundant *Aedes aegypti* populations.<sup>16</sup> Using phylogenetic analyses of ZIKV from clinical and mosquito samples without passage through cell culture, researchers estimate that ZIKV was likely introduced into Florida at least two months prior to its first detected human case.<sup>15</sup> Because of international travel, outbreaks in the U.S. will likely correspond with ZIKV outbreaks in other parts of the world where *Aedes aegypti* mosquitoes are in abundance.

**MODES OF TRANSMISSION**

Current evidence supports the following modes of transmission of ZIKV to humans: mosquito-borne transmission, sexual transmission, intrauterine transmission and transmission through blood transfusion.<sup>17,18</sup> While the *Aedes aegypti* mosquito is most commonly responsible for transmission of ZIKV to humans, *Aedes albopictus* can also transmit ZIKV.<sup>19,20</sup> Transmission of ZIKV through sexual intercourse has been reported in male-to-female, male-to-male, and female-to-male sexual contact.<sup>17,21-27</sup> In addition to the four modes of transmission, rare cases of intrapartum transmission and transmission from laboratory exposure have also been reported.<sup>17,18</sup>

**CLINICAL MANIFESTATIONS & MANAGEMENT**

The most common symptoms associated with human ZIKV infection include fever, a maculopapular rash, arthralgias, and non-purulent conjunctivitis. Other symptoms that have been reported from the outbreak in Yap Island include headache, myalgias, retro-orbital pain, edema and vomiting,<sup>6,28</sup> as shown in Table 1. Approximately 80 percent of individuals infected with ZIKV are asymptomatic.<sup>6</sup> The incubation period of ZIKV infection varies between three and 14 days.<sup>29</sup> The course of the infection is typically self-limiting, with symptoms lasting for several days to a week.<sup>30</sup> Severe disease requiring hospitalization is uncommon and mortality remains low, with one death reported in 153 hospitalized patients.<sup>11,31</sup> Supportive care of symptomatic patients and fetal surveillance of pregnant women is the mainstay of management for people infected with ZIKV.<sup>31,32</sup>

**TABLE 1:**  
Symptoms of Zika

MOST COMMON SYMPTOMS OF ZIKA	ADDITIONAL SYMPTOMS
Fever	Retro-orbital pain
Maculopapular rash	Edema
Headache	Vomiting
Arthralgia	
Non-purulent conjunctivitis	
Myalgias	

**COMPLICATIONS OF ZIKA VIRUS INFECTION IN ADULTS**

The complication of greatest concern in adults infected with ZIKV is Guillain-Barré syndrome (GBS), an immune mediated progressive neurologic disorder characterized by tingling, progressive weakness, autonomic dysfunction and pain.<sup>33</sup> GBS has been associated with many infections, most notably *Campylobacter jejuni*, but also other flaviviruses such as JEV, WNEV and DENV.<sup>33,34,35</sup> During the French Polynesia ZIKV outbreak of 2013-2014, 32,000 people sought medical attention for possible ZIKV infection and 42 patients were identified with GBS.<sup>35</sup> This represents a 20-fold increase over baseline incidence of GBS in this population.<sup>34</sup> Associations between the incidence of ZIKV and GBS have been observed during outbreaks in Brazil, Colombia, Dominican Republic, El Salvador, Honduras, Panama, Suriname, and Venezuela.<sup>36, 37</sup> A WHO expert panel reviewed the data and concluded that ZIKV is a trigger for GBS.<sup>35</sup>

**COMPLICATIONS IN INFANTS BORN TO MOTHERS INFECTED WITH ZIKV DURING PREGNANCY**

A comprehensive review of the literature relative to ZIKV infection in French Polynesia, Brazil, U.S. and Spain identified a constellation of symptoms, now recognized as Congenital Zika Syndrome (CZS).<sup>38</sup> The main features of this syndrome are abnormal cranial morphology, brain anomalies, neurologic sequelae, ocular anomalies, and congenital contractures, with specific examples including fetal brain disruption sequence, cerebral cortex thinning, epilepsy, cataracts, and arthrogryposis.<sup>38</sup> Continued surveillance and reporting should help better define this syndrome in the future.

The breadth of impact of maternal intrauterine ZIKV infection in the U.S. is still being monitored. The CDC, in collaboration with state, territorial, tribal, and local health departments, has created a registry known as the U.S. Zika Pregnancy Registry (USZPR),

which monitors birth defects in infants born in the U.S. to women potentially infected with ZIKV during pregnancy.<sup>39</sup> A detailed list of possible birth defects and instructions on how to report them is available through the CDC.<sup>40</sup> As of January 2018, the USZPR has reported 17 pregnancy losses with evidence of ZIKV-associated birth defects and 6,106 completed pregnancies with laboratory evidence of possible ZIKV infection among women in the U.S., District of Columbia, U.S. Territories and Freely Associated States.<sup>41</sup> Of the 6,106 completed pregnancies, there were 247 live-born infants with evidence of ZIKV-associated birth defects (4%). A 2017 study evaluated 442 pregnant women and pregnancy outcomes from the USZPR and concluded that 6% of infants had evidence of birth defects, with the rate of birth defects increasing to 11% when the mother was infected in the first trimester.<sup>41, 42</sup> Microcephaly was the most common defect, reported at a rate of 4%, which falls between the rates of birth defects seen in French Polynesia (0.95%) and estimated in Bahia, Brazil (13.2%).<sup>43, 44</sup>

## DIFFERENTIAL DIAGNOSIS

Considering current epidemiologic trends, the most relevant differential diagnoses to consider are CHIKV and DENV. High fever ( $\geq 104^{\circ}\text{F}$ ) is an important distinguishing characteristic of Dengue while fever and severe joint pain may be more indicative of Chikungunya.<sup>45, 46</sup> Table 2 provides an inclusive list of differential diagnoses, including other mosquito-borne illnesses and infections that present with fever, rash and arthralgia or myalgia. Currently, the CDC recommends testing for DENV and CHIKV for patients at risk of clinically compatible illness.<sup>47</sup> If other diagnoses are suspected at the time of presentation, specific testing should be pursued as well.<sup>47</sup> While awaiting laboratory confirmation of ZIKV, it is important to avoid the use of nonsteroidal anti-inflammatory medications in all patients with suspected DENV due to the increased risk of hemorrhagic complications.<sup>48</sup>

## DIAGNOSTIC APPROACH TO PATIENTS WITH POSSIBLE ZIKV EXPOSURE

Currently, there are three main arms of testing for ZIKV infection: Nucleic amplification testing assays (NAT), Anti-Zika IgM serology assays (Zika IgM), and the plaque reduction neutralization test (PRNT). As of January 2018, the FDA has approved 14 NAT and 5 Zika IgM assays for emergency use.<sup>49</sup> A positive NAT result represents the presence of ZIKV RNA in the host specimen sample. NAT is routinely performed on serum and urine samples; however, other fluid and tissue samples, such as cerebrospinal fluid, placental tissue, and amniotic fluid are also under investigation.<sup>50, 51</sup> Since ZIKV RNA is only transiently present in any body fluid, a positive NAT suggests an acute infection.<sup>50, 52, 53</sup> ZIKV IgM assays detect anti-ZIKV IgM antibodies that normally become detectable within 1 week of symptom onset.<sup>32</sup> Though data is limited, one recent study showed that ZIKV IgM may persist for up to 43 days in serum and that the duration of detection varies based on the assay being used.<sup>54</sup> Thus, positive ZIKV IgM is suggestive of ZIKV infection, but does not identify the timing of infection.<sup>47</sup> Given a large cross reactivity between flavivirus antibodies and a false positive rate up to 27% in the U.S., PRNT is used as a confirmatory test to differentiate ZIKV IgM antibodies from other flavivirus antibodies present in the host.<sup>50, 55</sup> However, in areas of high DENV circulation, PRNT does not differentiate between ZIKV and DENV IgM.<sup>56</sup> Thus, PRNT should not be used in areas such as Puerto Rico,

**TABLE 2:**

Differential Diagnoses

PRESENTATION	DIAGNOSES
Fever, Rash and Arthralgia/Myalgia	Zika Lyme Disease Dengue Rickettsiosis Chikungunya
Fever and Rash	Rubella Measles Parvovirus Adenovirus Scarlet Fever Ehrlichiosis
Fever and Arthralgia/Myalgia	Yellow Fever Leptospirosis West Nile Encephalitis* Malaria

\*Most cases are asymptomatic

which have high rates of DENV infection.<sup>50</sup>

Given the changing epidemiology of ZIKV infection and the limitation of available testing, the CDC continuously updates its algorithm for laboratory testing and confirmation of diagnosis.<sup>32</sup> Table 3 summarizes the most recent testing recommendations for pregnant and non-pregnant individuals, released in January 2018 and July 2017 respectively. The most recent updates recommend initial testing with NAT of both serum and urine and/or ZIKV IgM testing.<sup>32, 50, 51</sup> The choice of test is based upon type of exposure, symptom, pregnancy status, and time since symptom onset.<sup>32, 50, 51</sup> Exposure is further categorized as ongoing or limited risk of ZIKV transmission. The term ongoing exposure refers to living in or frequent travel to an area with a risk of Zika or sexual intercourse with a partner who lives in or frequently travels to an area with a risk of Zika. The term limited exposure refers to limited travel to an area with a risk of Zika or sexual intercourse with a partner who has traveled to an area with a risk of Zika. The CDC travel pages provide updated information regarding areas worldwide and in the U.S. at risk of ZIKV infection.<sup>57, 58</sup> The term symptomatic refers to patients presenting with any of the following symptoms of ZIKV infection: maculopapular rash, conjunctivitis, fever or arthralgia.<sup>47</sup>

## PREVENTION OF MOSQUITO-BORNE TRANSMISSION OF ZIKV

For people living in or traveling to areas at risk of Zika, preventing contact between mosquitoes and humans is the primary method of reducing infection. Bite prevention should be multimodal, including use of insect repellent, protective clothing, and environmental precautions. Insect repellents containing the following active ingredients have been approved and are endorsed by the CDC and Environmental Protection Agency (EPA): N,N-Diethyl-meta-toluamide (DEET), picaridin, IR35, Oil of Lemon Eucalyptus, para-menthane-diol, and 2-undecanone.<sup>59</sup> The most effective repellents against the *Aedes aegypti* mosquito contain

TABLE 3:

CDC recommendation for laboratory testing and result interpretation for patients with possible exposure to ZIKV

TIMEFRAME	INITIAL TEST	INTERPRETATION OF TEST RESULTS
Symptomatic Nonpregnant		
< 2 weeks from symptom onset	NAT serum and urine for ZIKV	Positive: diagnostic for acute ZIKV Infection Negative: ZIKV unlikely
> 2 and < 12 weeks from symptom onset	IgM serology for ZIKV	Positive or equivocal: PRNT testing to confirm diagnosis, if ZIKV $\geq$ 10 and DENV < 10: confirms ZIKV infection, though timing of infection cannot be determined Negative: ZIKV unlikely
Symptomatic Pregnant		
Up to 12 weeks from symptom onset	NAT serum and urine for ZIKV and IgM for ZIKV*	Either urine or serum NAT Positive and IgM positive: diagnostic for acute ZIKV infection NAT not concordant** and IgM negative: retest original positive sample (urine or serum) for NAT, if negative then test serology 2 weeks from date of original test NAT and IgM negative: no evidence of ZIKV infection
Asymptomatic Pregnant: Ongoing Exposure		
Upon initiation of prenatal care	NAT urine and serum for ZIKV***	Positive: diagnostic for ZIKV infection, no further Zika testing needed Negative: ZIKV infection in pregnancy cannot be ruled out. Retest with NAT two more times in pregnancy.†
Asymptomatic Pregnant: Limited Exposure		
Upon initiation of prenatal care if case-by-case decision making† suggests testing	NAT urine and serum for ZIKV	Positive: diagnostic for ZIKV infection, no further Zika testing needed Negative: ZIKV infection in pregnancy cannot be ruled out. Retest with NAT two more times in pregnancy.†

Abbreviations: NAT = Nucleic amplification testing; ZIKV = Zika virus; PRNT = Plaque-reduction neutralization test Information from references (32, 47, 50)

\* Given the extended presence of viral particles in body fluids during pregnancy, all symptomatic pregnant women undergo both NAT-serum/urine and ZIKV IgM testing at initial presentation of symptoms

\*\* Positive urine NAT and negative serum NAT or negative urine NAT and positive serum NAT

\*\*\* CDC does not currently recommend IgM serology because IgM can persist for months after ZIKV infection, thus a positive serology result cannot reliably determine if the infection took place before or during pregnancy.

† At non-coinciding prenatal visits, additional testing may be warranted depending on local trends in ZIKV transmission

‡ Given high rate of false positives of NAT and IgM in areas of low-risk, case-by-case decision making between provider and patient should inform the decision to test.

DEET (>5%) and picaridin (16%). However, products containing 25% DEET provide protection for the longest duration of time.<sup>60,61</sup> The American Academy of Pediatrics cautions against the use of DEET containing products in infants less than 2 months of age.<sup>62</sup>

*Aedes aegypti* bite during the day and night and dwell both indoors and outdoors. Long sleeved shirts, long pants, socks, and hats are recommended to cover bare skin.<sup>63</sup> In areas where there is no permethrin resistance, permethrin treated clothes are also effective at repelling mosquitoes.<sup>64,65</sup> Environmental precautions can also decrease exposure. Keeping windows and doors closed or screened and using air conditioning, can reduce the number of mosquitoes present in daytime and nighttime environments. Covering any holes or gaps between doors, walls, and screens can further secure the indoor environment.<sup>65</sup> If sleeping outside, insecticide treated bed nets are recommended.<sup>64,65</sup>

To prevent continued dissemination of ZIKV, it is also important to prevent transmission from infected humans to mosquitoes. Because humans infected with ZIKV are viremic during the first week of illness and can transmit the virus to a biting mosquito, it is recommended that patients with known ZIKV infection take precautions to prevent mosquito bites during this time.<sup>66,67</sup> Travelers returning from areas of possible ZIKV infection should prevent mosquito bites for three weeks, which safely covers the range of the ZIKV incubation period and the length of viremia.<sup>66</sup>

According to the CDC and the U.S. EPA, one of the most effective means of decreasing a mosquito population is to remove the habitat and thus interrupt the life cycle at the larval and adult stages. Monitoring areas with standing water is an important aspect of mosquito population control since mosquitoes rely on water for two stages of their life cycle. Areas with standing water, such as old tires, gutters, or toys containing water should be drained, scrubbed and covered. Birdbaths, fountains, or potted plant trays should be emptied and scrubbed once a week. The addition of larvicides to breeding habitats is very effective in reducing populations in nearby locations. Aerial spraying of adulticides, either by aircraft, truck-mounted or backpack sprayers, is effective in reducing the total number of adult mosquitoes over larger areas.<sup>65</sup>

## PREVENTION OF SEXUAL TRANSMISSION OF ZIKV & PRECONCEPTION COUNSELING TO PREVENT INTRAUTERINE TRANSMISSION

Though not as common as transmission from mosquitoes, sexual transmission poses an important modifiable risk that, if addressed, can help prevent birth defects associated with ZIKV. To reduce the risk of sexual transmission of ZIKV, all men and women who live in or travel to areas at risk of ZIKV infection should use barrier methods or abstain from vaginal, anal or oral sex.<sup>22</sup> Furthermore, to help prevent possible adverse outcomes in pregnancy, ZIKV prevention counseling should be a routine part of care for women of reproductive age. To promote early detection of ZIKV before and during pregnancy, the American College of Obstetricians and Gynecologists (ACOG) recommends that all women should be informed of the common symptoms of ZIKV infection (Table 1).<sup>68</sup> If pregnancy is not desired, strategies to prevent pregnancy,

including family planning and contraceptive options, should be discussed.<sup>22</sup>

For women with ongoing ZIKV exposure who desire pregnancy, the health professional should discuss the possible adverse outcomes of ZIKV infection during pregnancy. Women and their partners should be informed of mosquito bite prevention strategies and reassured that if used according to product labels, EPA registered mosquito repellents can be used safely before and during pregnancy.<sup>69</sup> If a woman with ongoing ZIKV exposure does become pregnant, she should initiate prenatal care immediately and undergo ZIKV testing.<sup>32</sup>


For women with limited ZIKV exposure who desire pregnancy, the health professional should recommend avoiding travel to areas at risk of ZIKV infection.<sup>32</sup> If she or her sexual partner must travel to these areas, they should follow the recommendations listed above to help prevent mosquito bites while traveling. If the woman is possibly exposed to ZIKV through travel or sexual contact with a partner who has traveled, she should prevent conception for the next eight weeks either by abstaining from or using condoms during sexual intercourse.<sup>22,32</sup> ZIKV may be passed through sexual transmission from an asymptomatic male.<sup>22,70,71</sup> and ZIKV RNA has been found in semen up to 188 days after symptom onset.<sup>22,72</sup> Because of this evidence, the CDC recommends that males should abstain from sex or use condoms for six months following possible exposure.<sup>22</sup> If females become symptomatic, they should avoid unprotected sex for eight weeks from the date of symptom onset or Zika diagnosis. If males become symptomatic, they and their female partners should avoid unprotected sex for six months from the date of symptom onset or Zika diagnosis in the male.<sup>22</sup> Should the woman become pregnant, she should initiate prenatal care immediately. The need for ZIKV testing would be determined based on the degree of possible exposure and shared decision making.<sup>32</sup>

## CONCLUSION

An approach to patients with possible ZIKV exposure is illustrated in Figure 1. Armed with this knowledge, through counseling and early detection, the medical community can help prevent the spread of ZIKV and its potential complications. In the absence of FDA approved antivirals and vaccines, the onus for preventing ZIKV infection falls on mosquito eradication efforts, as well as early detection and management. The rapid emergence of ZIKV in the Americas highlights the importance of a gene-based, global surveillance network that can identify the increasing presence of new or reemerging viruses and implement prevention initiatives such as mosquito eradication and immunization programs when available.

FIGURE 1:

Primary Care Approach to Patient with Possible ZIKV Exposure.

**AUTHOR DISCLOSURES:**

No relevant financial affiliations

**REFERENCES**

1. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. 1 February 2016. <http://www.who.int/mediacentre/news/statements/2016/1st-emergency-committee-zika/en/>
2. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus *Flavivirus*. *J Virol*. 1998;72(1):73-83.
3. Dick, GWA. Zika virus (II). Pathogenicity and physical properties. *Transactions of The Royal Society of Tropical Medicine and Hygiene*. 1952;46(5):521-534. [https://doi.org/10.1016/0035-9203\(52\)90043-6](https://doi.org/10.1016/0035-9203(52)90043-6)
4. Marchette NJ, Garcia R, Rudnick A. Isolation of Zika virus from *Aedes aegypti* mosquitoes in Malaysia. *Am J Trop Med Hyg*. 1969;18(3):411-5.
5. Olson JG, Ksiazek TG, Suhandiman, Triwibowo. Zika virus, a cause of fever in Central Java, Indonesia. *Trans R Soc Trop Med Hyg*. 1981;75(3):389-93.
6. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med*. 2009;360(24):2536-43. doi: 10.1056/NEJMoa0805715.
7. Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, et al. Genetic Characterization of Zika Virus Strains: Geographic Expansion of the Asian Lineage. *PLoS Negl Trop Dis* 2012; 6(2): e1477. doi:10.1371/journal.pntd.0001477
8. Musso D, Gubler DJ. Zika virus. *Clin Microbiol Rev* 2016; 29:487-524. doi:10.1128/CMR.00072-15.
9. Metsky HC, Matranga CH, Wohl S, Schaffner SF, Freije CA et al. Zika virus evolution and spread in the Americas. *Nature* 2017;546(7658):411-415. doi: 10.1038/nature22402.
10. Florida Department of Health Daily Zika Update: the Department Responds to Local Zika Cases. July 29, 2016. <http://www.floridahealth.gov/newsroom/2016/07/072916-local-zika.html>
11. Hall V, Walker WL, Lindsey NP, et al. Update: Noncongenital Zika Virus Disease Cases – 50 U.S. States and the District of Columbia, 2016. *MMWR Morb Mortal Wkly Rep* 2018;67:265-269. DOI: <http://dx.doi.org/10.15585/mmwr.mm6709a1>
12. McCarthy M. First US case of Zika virus infection is identified in Texas. *BMJ* 2016;352:i212. doi: 10.1136/bmj.i212.
13. Adalja AA, Sell T, Bouri N, Franco C. Lessons Learned during Dengue Outbreaks in the United States, 2001-2011. *Emerg Infect Dis*. 2012;18(4):608-614. <https://dx.doi.org/10.3201/eid1804.110968>
14. CDC. Chikungunya virus in the United States. August, 2015. Augusta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/chikungunya/geo/united-states.html>
15. Grubaugh ND, Ladner JT, Kraemer MUG, Dudas G, Tan AL, et al. Genomic epidemiology reveals multiple introductions of Zika virus into the United States. *Nature* 2017;546(7658):401-405. doi: 10.1038/nature22400.

17. Dzul-Manzanilla F, Martínez NE, Cruz-Nolasco M, Gutiérrez-Castro C, López-Damián L, et al. Evidence of vertical transmission and co-circulation of chikungunya and dengue viruses in field populations of *Aedes aegypti* (L.) from Guerrero, Mexico. *Trans R Soc Trop Med Hyg*. 2016;110(2):141-4. doi: 10.1093/trstmh/trv106.
18. Gregory CJ, Oduyebo T, Brault AC, et al. Modes of transmission of zika virus. *J Infect Dis*. 2017;216:S875-S883.
19. Sharma A, Lal SK. Zika virus: Transmission, detection, control, and prevention. *Frontiers in microbiology*. 2017;8:110.
20. Wong PJ, Li MI, Chong C, Ng L, Tan C. *Aedes (stegomyia) albopictus* (skuse): A potential vector of zika virus in singapore. *PLoS Neglected Tropical Diseases*, 2013;7(8): 1.
21. Grard G, Caron M, Mombo IM, et al. Zika virus in Gabon (Central Africa) – 2007: A new threat from *aedes albopictus*? *PLoS neglected tropical diseases*. 2014;8(2):1.
22. Sherley M, Ong C. Sexual transmission of zika virus: A literature review. *Sexual health*. 2017.
23. Petersen EE, Meaney-Delman D, Neblett-Fanfair R, et al. Update: Interim Guidance for Preconception Counseling and Prevention of Sexual Transmission of Zika Virus for Persons with Possible Zika Virus Exposure – United States, September 2016. *MMWR Morb Mortal Wkly Rep* 2016;65:1077-1081. DOI: <http://dx.doi.org/10.15585/mmwr.mm6539e1>.
24. Foy BD, Kobylinski KC, Chilson Foy J, L., et al. Probable non-vector-borne transmission of zika virus, Colorado, USA. *Emerging infectious diseases*. 2011;17(5):880-882.
25. Hills SL, Russell K, Hennessey M, et al. Transmission of zika virus through sexual contact with travelers to areas of ongoing transmission - continental United States, 2016. *MMWR Morb Mortal Wkly Rep* 2016;65(8):215-216.
26. Venturi G, Zammarchi L, Fortuna C, et al. An autochthonous case of Zika due to possible sexual transmission, Florence, Italy, 2014. *Euro Surveill* 2016;21:30148.
27. Deckard DT, Chung WM, Brooks JT, et al. Male-to-male sexual transmission of Zika virus – Texas, January 2016. *MMWR Morb Mortal Wkly Rep* 2016;65:372-4.
28. Davidson A, Slavinski S, Komoto K, Rakeman J, Weiss D. Suspected female-to-male sexual transmission of Zika virus – New York City, 2016. *MMWR Morb Mortal Wkly Rep* 2016;65:716-7.
29. PAHO. Epidemiological Alert: neurological syndrome, congenital malformations, and Zika virus infection. Implications for public health in the Americas. 1 December 2015. Washington, DC: World Health Organization, Pan American Health Organization.
30. Krow-Lucal ER, Biggerstaff BJ, Staples J. Estimated Incubation Period for Zika Virus Disease. *Emerg Infect Dis*. 2017;23(5):841-845. <https://dx.doi.org/10.3201/eid2305.161715>
31. CDC. Symptoms. May 2017. <https://www.cdc.gov/zika/symptoms/symptoms.html>
32. CDC. Clinical Evaluation and Disease. December, 2017. <https://www.cdc.gov/zika/hc-providers/preparing-for-zika/clinicalevaluationdisease.html>
33. Oduyebo T, Polen KD, Walke HT, et al. Update: Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States (Including U.S. Territories), July 2017. *MMWR Morb Mortal Wkly Rep* 2017;66:781-793. DOI: <http://dx.doi.org/10.15585/mmwr.mm6629e1>.
34. Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana, C, Monsalve, DM, et al. Guillain-Barré syndrome, transverse myelitis and infectious diseases. *Cell Mol Immunol* 2018; doi: 10.1038/cmi.2017.142. [Epub ahead of print]
35. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastère S, Valour F, et al. Zika virus infection complicated by Guillain-Barré syndrome – case report, French Polynesia, December 2013. *Euro Surveill*. 2014;19(9):pii=20720. <https://doi.org/10.2807/1560-7917.ES2014.19.9.20720>
36. Krauer F, Riesen M, Reveiz L, Oladapo OT, Martínez-Vega R, Porgo TV, et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: systematic review. *PLoS Med* 2017;14(1):e1002203. doi:10.1371/journal.pmed.1002203
37. Smith DW, Mackenzie, J. Zika virus and Guillain-Barré syndrome: another viral cause to add to the list. *The Lancet*, 2016;387(10027):1486-1488.
38. Dos Santos T, Rodriguez A, Almiron M, Sanhueza A, Ramon P, de Oliveira WK, et al. Zika virus and the Guillain-Barré syndrome – case series from seven countries. *N Engl J Med* 2016;375(16):1598-1601.
39. Moore CA, Staples JE, Dobyns WB, et al. Characterizing the pattern of anomalies in congenital zika syndrome for pediatric clinicians. *JAMA pediatrics*. 2017;171(3):288-295.
40. CDC. US Zika and pregnancy infancy registry. January, 2018. GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/pregnancy/zika/research/registry.html>
41. CDC. Zika and Pregnancy, Technical and Clinical Information. January, 2018. GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/pregnancy/zika/research/technical-clinical.html>
42. CDC. Outcomes of Pregnancies with Laboratory Evidence of Possible Zika Virus Infection, 2015-2018. January, 2017. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html>
43. Honein MA, Dawson AL, Petersen EE, et al. Birth defects among fetuses and infants of US women with evidence of possible zika virus infection during pregnancy. *Jama*. 2017;317(1):59-68.
44. Cauchemez S, Besnard M, Bompard P, et al. Association between zika virus and microcephaly in french polynesia, 2013-15: A retrospective study. *Lancet (London, England)*. 2016;387(10033):2125-2132.
45. Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. Zika and the risk of microcephaly. *N Engl J Med*. 2016;375(1):1-4.
46. WHO. Dengue and Severe Dengue. April, 2017. Geneva: World Health Organization. Retrieved from: <http://www.who.int/mediacentre/factsheets/fs117/en/>
47. CDC. Chikungunya Virus: What You Need to Know. September, 2015. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: [https://www.cdc.gov/chikungunya/pdfs/factsheet\\_chikungunya-what-you-need-to-know.pdf](https://www.cdc.gov/chikungunya/pdfs/factsheet_chikungunya-what-you-need-to-know.pdf)
48. CDC. Zika virus testing guidance: symptomatic non-pregnant individuals with possible zika virus exposure. August, 2017. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/zika/pdfs/testing-algorithm-symptomatic-nonpregnant.pdf>
49. PAHO. Tool for diagnosis and care for patients with suspected arboviral disease. March, 2017. Washington, DC: World Health Organization, Pan American Health Organization. <http://iris.paho.org/xmlui/handle/123456789/33895>
50. FDA. Zika Virus Emergency Use Authorization. January, 2018. Silver Spring, MD. US Food and Drug Administration. Retrieved from: <https://www.fda.gov/medicaldevices/safety/emergencysituations/ucm161496.htm#zika>
51. CDC. Guidance for US Laboratories Testing for Zika Virus Infection. July 24, 2017. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/zika/laboratories/lab-guidance.html>

52. CDC. Zika and Pregnancy, Testing and Diagnosis. January, 2018. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/pregnancy/zika/testing-follow-up/testing-and-diagnosis.html> -
53. Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of zika virus associated with an epidemic, yap state, micronesia, 2007. *Emerging infectious diseases*. 2008;14(8):1232-1239.
54. Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of zika virus in body fluids - preliminary report. *N Engl J Med*. 2017.
55. Pasquier C, Jogue G, Mengelle C, et al. Kinetics of anti-ZIKV antibodies after zika infection using two commercial enzyme-linked immunoassays. *Diagn Microbiol Infect Dis*. 2018;90(1):26-30.
56. Woods CR. False-positive results for immunoglobulin M serologic results: Explanations and examples. *Journal of the Pediatric Infectious Diseases Society*. 2013;2(1):87-90.
57. Lindsey NP, Staples JE, Powell K, et al. Ability to serologically confirm recent zika virus infection in areas with varying past incidence of dengue virus infection in the united states and U.S. territories in 2016. *J Clin Microbiol*. 2018;56(1).
58. CDC. World maps of areas with risk of Zika transmission. February, 2018. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://wwwnc.cdc.gov/travel/page/world-map-areas-with-zika>
59. CDC. Guidance for areas with local Zika transmission in the continental United States and Hawaii. August, 2017. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/zika/geo/domestic-guidance.html>
60. Centers for Disease Control and Prevention. CDC Yellow Book 2018: Health Information for International Travel. Chapter 2 (19). New York: Oxford University Press; 2017.
61. Uc-Puc V, Herrera-Bojórquez J, Carmona-Carballo C, et al. Effectiveness of commercial repellents against *Aedes aegypti* (L.) in yucatan, méxico]. *Salud publica de Mexico*. 2016;58(4):472-475.
62. Fradin MS, Day JF. Comparative efficacy of insect repellents against mosquito bites. *N Engl J Med*. 2002;347(1):13-18.
63. American Academy of Pediatrics Committee on Environmental Health. Pesticides. In: Etzel RA, ed. *Pediatric Environmental Health*. 2nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003:348-350.
64. EPA. Success in Mosquito Control: An Integrated Approach. October, 2016. The United States Environmental Protection Agency. Retrieved from: <https://www.epa.gov/mosquitocontrol/success-mosquito-control-integrated-approach>
65. Goodyer LI, Croft AM, Frances SP, et al. Expert review of the evidence base for arthropod bite avoidance. *Journal of travel medicine*. 2010;17(3):182-192.
66. CDC. Response to Zika, Counseling Travelers. September, 2017. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/zika/pdfs/travelcounseling-fs.pdf>
67. CDC. Zika Key Messages. October, 2017. Atlanta, GA: US Department of Health and Human Services, CDC. Retrieved from: <https://www.cdc.gov/zika/pdfs/Zika-Key-Messages.pdf>
68. Krow-Lucal ER, Biggerstaff BJ, Staples J. Estimated Incubation Period for Zika Virus Disease. *Emerging Infectious Diseases*. 2017;23(5):841-845. doi:10.3201/eid2305.161715.
69. ACOG. Practice Advisory, Interim Guidance Care for Obstetric Patients During a Zika Virus Outbreak, Reproductive Counseling. September, 2017. The American College of Obstetricians and Gynecologists. <https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Interim-Guidance-for-Care-of-Obstetric-Patients-During-a-Zika-Virus-Outbreak>
70. ACOG. Practice Advisory, Interim Guidance Care for Obstetric Patients During a Zika Virus Outbreak, Prevention. October, 2016. The American College of Obstetricians and Gynecologists. <https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Advisories/Practice-Advisory-Interim-Guidance-for-Care-of-Obstetric-Patients-During-a-Zika-Virus-Outbreak>
71. Fréour T, Mirallié S, Hubert B, et al. Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April 2016. *Euro Surveill* 2016;21:30254.
72. Brooks RB, Carlos MP, Myers RA, et al. Likely sexual transmission of Zika virus from a man with no symptoms of infection—Maryland, 2016. *MMWR Morb Mortal Wkly Rep* 2016;65:915–6.
73. Nicastrì E, Castilletti C, Liuzzi G, Iannetta M, Capobianchi MR, Ippolito G. Persistent detection of zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. *Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin*. 2016;21(32).